EGFR
Beyond's analysis on EGFR
- — Johnson & Johnson’s RYBREVANT plus chemotherapy shows record overall survival in EGFR exon20‑insertion lung cancer, signaling a potential new standard of care
- — PTK7 emerges as stable ADC target in EGFR wild-type NSCLC, boosting Whitehawk's HWK-007 prospects
Recent news mentioning EGFR
- — Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
- — Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
- — SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026
- — HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
- — AstraZeneca Made a $1.5 Billion Lung Cancer Bet, but Can Zegfrovy Strengthen its Oncology Growth?
- — Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026